7.1 Subject Recruitment, Screening, and Enrolling Procedures

7.1 Subject Recruitment, Screening, and Enrolling Procedures

Clinical trial implementation begins with the acquisition of human subjects. Subject recruitment, screening, and enrollment are distinct, sequential phases of study execution. Each phase is governed by federal regulations—primarily 21 CFR Parts 50 (Protection of Human Subjects), 56 (Institutional Review Boards), and 45 CFR Part 46 (The Common Rule)—and International Council for Harmonisation (ICH) E6(R3) Good Clinical Practice (GCP) guidelines (SOCRA CCRP exam content reflects E6(R3) beginning January 1, 2026). The transition of an individual from a member of the general public or clinical patient pool to a fully enrolled clinical trial subject requires rigorous procedural control to ensure ethical standards, scientific validity, and data integrity.

1. Subject Recruitment and Advertising Materials

Subject recruitment represents the initial phase of public outreach or targeted identification. Any recruitment materials, advertisements, or methods designed to solicit participation from potential subjects are considered part of the informed consent process. Under 21 CFR 56.111(a)(4), the Institutional Review Board (IRB) must review and approve all recruitment materials prior to distribution or broadcast.

IRB Review Thresholds

Recruitment materials requiring IRB approval include flyers, posters, newspaper advertisements, radio and television scripts/recordings, email invitations, and digital/social media ads. The IRB reviews these materials to ensure they are not coercive and do not create undue influence.

Exemptions from IRB Review

Under Food and Drug Administration (FDA) Guidance, simple listings of clinical trials on public registries, such as ClinicalTrials.gov, do not require IRB review, provided the listing does not exceed basic directory information. This includes the study title, purpose, basic eligibility criteria, location, and contact details, and does not present any promotional claims or emphasize financial compensation.

Advertising Content Standards

Advertising must be strictly informative and neutral. The FDA and IRBs enforce explicit rules to prevent coercion or undue influence:

• No Coercive Claims: Ads must never state or imply that the investigational product (IP) is safe, effective, or superior to existing treatments. Terms like "new cure," "magic pill," or "FDA-approved treatment" are strictly prohibited for investigational drugs or devices.
• Financial Presentation: While compensation may be mentioned, it must not be emphasized, highlighted, or presented in a larger font than other information. The ad must not present compensation as a primary benefit or inducement to participate.
• Formatting and Tone: The tone must be clinical and educational. Visuals should not be misleading (e.g., showing a person completely cured of a disease).

2. Screening Procedures and Screening Logs

Screening occurs after a potential subject expresses interest but before they are formally enrolled. It involves collecting demographic, clinical, and laboratory data to determine if the subject meets all inclusion and exclusion criteria.

Informed Consent for Screening

Screening procedures that are not part of routine clinical care (e.g., an extra blood draw, a wash-out period of current medications, or a study-specific MRI) cannot be performed until the subject has signed the study-specific Informed Consent Form (ICF). However, if screening involves only reviewing existing medical records (pre-screening), a partial Health Insurance Portability and Accountability Act (HIPAA) waiver or IRB-approved pre-screening consent may suffice, depending on local institutional policies.

The Screening Log

The screening log is a critical source document that tracks all individuals who underwent screening. To protect subject privacy under HIPAA, names and full medical record numbers are typically omitted, and unique identifiers are used. The screening log must record:

• Screening number or unique identifier.
• Date of screening.
• Inclusion/exclusion criteria checklist status.
• Eligibility determination (Eligible vs. Screen Failure).
• Reason for screen failure (e.g., lab value out of range, patient withdrew consent, did not meet inclusion criteria).

Scientific and Operational Purpose

Scientifically, screening logs help detect selection bias. For instance, if 90% of screened candidates fail due to a single restrictive exclusion criterion, it may indicate that the study population is not representative, or that the protocol is operationally unfeasible. Under ICH GCP, monitors inspect screening logs to verify that the investigator is recruiting and selecting subjects in accordance with the protocol.

3. Randomization and Blinding

Once a subject is confirmed eligible, they proceed to randomization, if required by the study design. Randomization is the process of assigning trial subjects to treatment or control groups using an element of chance, ensuring that each subject has an equal probability of assignment.

Purpose

Randomization minimizes selection bias and balances both known and unknown confounding variables across treatment arms, enhancing the validity of statistical inferences.

Interactive Response Systems

In modern clinical trials, randomization is managed electronically using Interactive Voice Response Systems (IVRS) or Interactive Web Response Systems (IWRS). The investigator or designated coordinator inputs the subject’s eligibility confirmation into the system, which then assigns a randomization number and specifies which kit/vial of IP to dispense.

Blinding (Masking)

Blinding prevents bias in treatment assessment:

• Single-blind: Only the subject is unaware of the treatment assignment.
• Double-blind: Both the subject and the investigator/clinical staff are unaware of the assignment.
• Triple-blind: The subject, investigator/staff, and data analysts/sponsor monitors are all blinded.

Emergency Unblinding

If a subject experiences a severe adverse event where medical management depends on knowing the actual treatment assignment, emergency unblinding may be performed. The protocol must specify the procedure (e.g., contacting the medical monitor or using a sealed envelope/electronic IWRS override). The investigator must document the date, time, reason, and personnel involved in the unblinding, and immediately notify the sponsor.

4. Enrollment Logs and Procedures

A subject is considered officially enrolled when they satisfy all eligibility criteria, have signed the ICF, and have been randomized or received their first dose of the IP (depending on the protocol's definition).

The Enrollment Log

The enrollment log is a chronological record of all subjects who entered the active phase of the trial. Unlike the screening log, which lists everyone who was tested, the enrollment log lists only those who successfully met the criteria and were randomized.

Required Fields

Key parameters on the enrollment log include:

• Subject study ID (e.g., Subj-001).
• Subject initials (if permitted by local privacy rules).
• Date of informed consent.
• Date of randomization/enrollment.
• Treatment assignment (if open-label) or kit assignment number.
• Date of study completion or premature withdrawal (and reason).

Comparison Table: Screening vs. Enrollment Logs

5. Regulatory Inspections and Best Practices

FDA inspections regularly audit screening and enrollment logs. A common finding is "Failure to Consent Prior to Screening," where sites perform study-specific tests (like wash-outs or specialized tests) before the subject signs the ICF. Another common finding is "Coercive Recruitment Advertisements," where the site utilized non-approved print or digital ads that exaggerated the benefits or offered excessive compensation. To avoid these traps, sites must establish robust SOPs that mandate informed consent signature as the absolute first step in any study-related activity.